Enlighten Study: The EV-ICD Post Approval Registry

Purpose

Medtronic is sponsoring Enlighten: The EV-ICD Post Approval Registry, to further confirm safety and effectiveness of EV-ICD in routine clinical practice, following commercial release of EV-ICD devices.

Conditions

  • Ventricular Arrhythmia
  • Tachycardia

Eligibility

Eligible Ages
All ages
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements - Patient is intended to receive or be treated with a EV-ICD device System and must be enrolled prior to the EV-ICD device implant procedure

Exclusion Criteria

  • Patient who is, or is expected to be, inaccessible for follow-up - Patient is excluded by local local law - Patient is currently enrolled or plans to enroll in any concurrent drug and/or device study that may confound the PSR results

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Recruiting Locations

University of Kansas Medical Center Research Institute
Kansas City, Missouri 66160
Contact:
Martin Emert, MD

More Details

Status
Recruiting
Sponsor
Medtronic

Study Contact

EV-ICD PAS/PMCF Study manager
18006338766
rs.productsurveillanceregistry@medtronic.com

Detailed Description

The Enlighten Study is a global, prospective, observational, multi-site registry study. This study is conducted within Medtronic's post-market surveillance platform. Eligibility for enrollment is based on market release dates for EV-ICD System within the geography in which the subject is enrolled. Patients enrolled in the Enlighten Study will be prospectively followed for the life time of device post-implant or until registry closure, patient death or patient exit from the registry (i.e., withdrawal of consent). Successfully implanted patients are expected to have scheduled follow-up visits per routine clinical care, at least annually, or as prompted by reportable adverse events. The total estimated registry duration is through lifetime of device.